Boulding Mark Elliott, Executive Vice President and Chief Legal Officer, has demonstrated a clear selling bias in his recent insider trading activity, as evidenced by SEC Form 4 filings. Over the course of 68 transactions, Elliott has exclusively traded shares of PTC Therapeutics, Inc. (PTCT), with a total buy value of approximately $3.35 million and a total sell value of nearly $6.88 million. Notably, all 22 of his most recent transactions, spanning from January 5, 2026, to February 19, 2026, were sales, with no purchases recorded during this period. These sales ranged in value from $140.26 to $213,698.16, reflecting a pattern of liquidating significant portions of his holdings.
The transactions were executed in clusters, particularly around mid-January and mid-February 2026, suggesting a structured approach to reducing his position in PTCT. For example, on February 19, 2026, Elliott sold shares totaling $113,736.78, $41,193.80, $40,301.52, and $14,530.48 in separate transactions. Similarly, on January 7, 2026, he conducted multiple sales, including $126,306.18, $116,452.44, and $73,936.59, among others. This consistent selling activity indicates a deliberate effort to divest from PTCT, though the filings do not provide insight into the underlying reasons for these transactions. Elliott’s trading history underscores a significant reduction in his equity stake in the company over this period.
AI-assisted summary